Abstract
This article describes a global project developed by WHO, the international Union against Tuberculosis and Lung disease and other partners to investigate anti-tuberculosis drug resistance across 79 included countries. It was found that almost all countries with high rates having a history of poor TB control. The results of this study suggest that in these countries, new control initiatives such as DOTS (http://www.who.int/tb/dots/whatisdots/en/index.html) should be instated to reduce the pressure of multi-drug resistant TB (MDRTB). Tuberculosis infects one-third of the world’s nearly 7 billion people and multi-drug resistance (MDR) is an evolving problem in many areas of the world, it has been decades since new anti-tuberculosis therapies have come to the market. The methods of the study were straightforward: new cases were differentiated from previously treated cases and a ‘supranational’ laboratory set quality standards. Developed and developing countries are included as are rich and poor countries, ranging from El Salvador to Oman, Norway to The Gambia. Data were reported as means and ranges of percent resistant to isoniazide, rifampicin, ethambutol, streptomycin and a combination of drugs (multi-drug resistance). A few countries like Iceland had no resistance whilst others had very high rates, such as Kazakhstan which reported a prevalence of 57%. Median prevalence for multi-drug resistance for all countries was 1.1%; the rate for MDR in the U.S. Low prevalence in highly populated countries still represents large absolute numbers of new MDRTB cases. This study also showed that HIV surveillance can be coupled with TB surveillance in many countries of Africa where HIV prevalence is high. The bad news is that a new emergent strain of so-called extensive drug resistance (XDR) throws a pall over even the good news of the analysis.